Q4 2024 Regenxbio Inc Earnings Call Transcript
Key Points
- Regenxbio Inc (RGNX) has submitted its first Biologics License Application (BLA) for RGX-121, targeting Hunter syndrome, with potential FDA approval expected in Q4 2025.
- The company is advancing its diabetic retinopathy program into a pivotal stage, with plans for future BLA filings for RGX-202 for Duchenne Muscular Dystrophy and ABBV-RGX-314 for Wet AMD.
- Regenxbio Inc (RGNX) has a strong partnership with Nippon Shinyaku, enhancing its commercial capabilities and providing potential milestones and revenue.
- The company is well-positioned with robust commercial capabilities and global partners, aiming for sustainable profitability through its gene therapy leadership.
- Regenxbio Inc (RGNX) has a solid financial position with $245 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2026.
- Regenxbio Inc (RGNX) experienced a decrease in cash and marketable securities from $314 million to $245 million over the year, primarily due to funding operating activities.
- The company faces risks and uncertainties associated with forward-looking statements, which may cause actual results to differ from forecasts.
- There is a potential regulatory approval risk for the priority review voucher (PRV) associated with RGX-121, which could impact non-dilutive financing options.
- The competitive landscape in the Wet AMD space poses challenges, with other long-acting TKI studies anticipated to read out in the same 2026 timeframe.
- Regenxbio Inc (RGNX) has not yet initiated studies in non-ambulatory patients for its Duchenne Muscular Dystrophy program, focusing resources on current pivotal trials.
Welcome, everyone, to the fourth-quarter and year-end 2024 REGENXBIO earnings conference call. (Operator Instructions)
Please be advised that today's conference is being recorded. At this time I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of REGENXBIO. Please go ahead.
Good afternoon and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the fourth-quarter and year ending December 31, 2024. The press release is available on our website at www.regenxbio.com.
Today's conference call will include forward-looking statements regarding our financial outlook, in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such aspect, plan, will, may,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
